Joel A. Van Roon

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial.

Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial.

Journal: The Lancet. Rheumatology

Published: October 23, 2025

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease.

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease.

Journal: Annals of the rheumatic diseases

Published: September 24, 2025

Proteomic Signatures Over Age Reveal Significant Changes From Infancy Till Late Adulthood.

Proteomic Signatures Over Age Reveal Significant Changes From Infancy Till Late Adulthood.

Journal: Advanced biology

Published: July 24, 2025

Lidocaine-induced tear production in primary Sjögren's disease: neurologically induced lacrimation to broaden the horizon for treatment of ocular dryness?

Lidocaine-induced tear production in primary Sjögren's disease: neurologically induced lacrimation to broaden the horizon for treatment of ocular dryness?

Journal: Annals of the rheumatic diseases

Published: July 03, 2025

Targeting B-cell activation to tackle both patient-reported and systemic disease outcomes in Sjögren's disease.

Targeting B-cell activation to tackle both patient-reported and systemic disease outcomes in Sjögren's disease.

Journal: The Lancet. Rheumatology

Published: May 14, 2025

Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI).

Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI).

Journal: Annals of the rheumatic diseases

Published: February 17, 2025

Proteins linked to type II interferon response in Sjögren's disease: novel indicators for disease monitoring and predicting treatment response to leflunomide and hydroxychloroquine combination therapy.

Proteins linked to type II interferon response in Sjögren's disease: novel indicators for disease monitoring and predicting treatment response to leflunomide and hydroxychloroquine combination therapy.

Journal: Frontiers in immunology

Published: January 24, 2025

Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren's disease.

Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren's disease.

Journal: Clinical immunology (Orlando, Fla.)

Published: August 18, 2023

CCR9/CXCR5 Co-Expressing CD4 T Cells Are Increased in Primary Sjögren's Syndrome and Are Enriched in PD-1/ICOS-Expressing Effector T Cells.

CCR9/CXCR5 Co-Expressing CD4 T Cells Are Increased in Primary Sjögren's Syndrome and Are Enriched in PD-1/ICOS-Expressing Effector T Cells.

Journal: International journal of molecular sciences

Published: April 24, 2023

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response.

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response.

Journal: RMD open

Published: January 02, 2023

Molecular and spatial analysis of tertiary lymphoid structures in Sjogren's syndrome.

Molecular and spatial analysis of tertiary lymphoid structures in Sjogren's syndrome.

Journal: Nature communications

Published: October 20, 2022

In patients with primary Sjögren's syndrome innate-like MAIT cells display upregulated IL-7R, IFN-γ, and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressing cells.

In patients with primary Sjögren's syndrome innate-like MAIT cells display upregulated IL-7R, IFN-γ, and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressing cells.

Journal: Frontiers in immunology

Published: August 11, 2022

Showing 1-12 of 94

Last Updated: 09/26/2026